Tg Therapeutics (TGTX) Common Equity (2011 - 2026)

Tg Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $583.1 million for Q1 2026.

• On a quarterly basis, Common Equity rose 145.75% year-over-year to $583.1 million in Q1 2026; TTM through Mar 2026 was $583.1 million, a 145.75% increase from a year earlier, with the FY2025 full-year figure at $648.0 million, up 191.42% from the prior year.
• Common Equity eased to $583.1 million in Q1 2026 per TGTX's latest filing, from $648.0 million in the prior quarter.
• Across five years, Common Equity topped out at $648.0 million in Q4 2025 and bottomed at $27.4 million in Q1 2023.
• The 5-year median for Common Equity is $170.4 million (2022), against an average of $232.7 million.
• Across the five-year window, Common Equity plunged 83.9% in 2023 and soared 483.64% in 2024, its largest moves.
• Year by year, Common Equity stood at $58.6 million in 2022, then surged by 173.95% to $160.5 million in 2023, then surged by 38.54% to $222.4 million in 2024, then soared by 191.42% to $648.0 million in 2025, then slipped by 10.01% to $583.1 million in 2026.
• Per Business Quant, the three latest TGTX Common Equity figures stand at $583.1 million (Q1 2026), $648.0 million (Q4 2025), and $607.2 million (Q3 2025).